Skip to main content
Clinical Trials/NCT00784602
NCT00784602
Terminated
Not Applicable

Observing Pelvic Organ Prolapse Symptoms And Treatment Outcomes

Melissa Fischer, MD1 site in 1 country301 target enrollmentOctober 29, 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Genital Prolapse
Sponsor
Melissa Fischer, MD
Enrollment
301
Locations
1
Primary Endpoint
Changes in urinary, bowel, and sexual function as measured on the PFDI, PFIQ, and PISQ validated questionnaires
Status
Terminated
Last Updated
8 years ago

Overview

Brief Summary

To prospectively observe the outcomes of surgical prolapse treatment in terms of urinary, bowel, and sexual function, quality of life, patient satisfaction, cost, and achieving patient determined treatment goals.

Detailed Description

Patients meeting the inclusion/exclusion criteria will be identified by reviewing the hospital's surgical boarding list and contacted by phone to obtain informed consent. Once informed consent is obtained, chart review will be conducted here at William Beaumont Hospital and at the physician's office to collect patient information related to their prolapse condition. Prior to surgery, questionnaires will be mailed and completed by the participant and then again at 6 and 12 months after surgery, and then yearly. Questionnaires will assess urinary, bowel, and sexual function, and patient treatment goals, treatment satisfaction, and general health and wellbeing. Completion of the questionnaires will be voluntary, and participants will be followed in this manner until voluntary withdrawal, exclusionary criteria emerge, or death.

Registry
clinicaltrials.gov
Start Date
October 29, 2008
End Date
August 29, 2016
Last Updated
8 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Melissa Fischer, MD
Responsible Party
Sponsor Investigator
Principal Investigator

Melissa Fischer, MD

Principal Investigator

William Beaumont Hospitals

Eligibility Criteria

Inclusion Criteria

  • Pelvic Organ Prolapse
  • Able to provide informed consent
  • Able to complete study assessments, per clinician judgment

Exclusion Criteria

  • Age \< 21 years
  • Currently pregnant or \< 6 months post-partum

Outcomes

Primary Outcomes

Changes in urinary, bowel, and sexual function as measured on the PFDI, PFIQ, and PISQ validated questionnaires

Time Frame: Ongoing

Study Sites (1)

Loading locations...

Similar Trials